表紙
市場調査レポート

米国の生物学的・組織エンジニアドデバイス - 心血管および神経学的製品

U.S. Markets for Biologic and Tissue Engineered Devices - Cardiovascular and Neurological Products

発行 Medtech Insight 商品コード 327399
出版日 ページ情報 英文 110 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=105.42円で換算しております。
Back to Top
米国の生物学的・組織エンジニアドデバイス - 心血管および神経学的製品 U.S. Markets for Biologic and Tissue Engineered Devices - Cardiovascular and Neurological Products
出版日: 2015年03月27日 ページ情報: 英文 110 Pages
概要

組織エンジニアリングあるいは再生医療は侵攻性疾患または死に至る疾患のための有望な治療方法となっています。特に心血管疾患や神経疾患のための細胞療法はドル箱市場です。現在35を超える細胞療法が米国をはじめ各国で開発されています。

当レポートでは、心血管疾患および神経疾患のための新興の細胞療法、新規の細胞療法を開発する企業の概要、現在開発中の細胞療法製品のための法規制認可取得予測、市場分析と将来予測などをまとめています。

第1章 組織エンジニアリングと細胞療法ツールと技術

  • バイオマテリアル
    • 生物由来のバイオマテリアル
    • 遺伝子組み換えバイオマテリアル
    • ハイブリッドバイオマテリアル
    • 合成バイオマテリアル
    • 足場
    • 血管
  • 細胞培養技術
    • バイオリアクター
  • 幹細胞技術
  • 免疫隔離技術

第2章 心血管疾患管理における組織エンジニアリングおよび細胞移植の新興の応用

  • 細胞療法と組織エンジニアリング
  • 細胞療法の投与
  • 幹細胞に基づく心筋組織修復と再生の臨床実績
  • 開発中の心筋組織修復と再生のための細胞療法
  • 重度の肢虚血患者における救肢のための新興の細胞療法
  • バイオエンジニアド血管
  • 現在および新興の米国の心血管関連組織エンジニアリングと細胞療法製品市場

第3章 神経疾患管理における組織エンジニアリングおよび細胞移植の新興の応用

  • 開発中の細胞療法に用いられる細胞の種類
  • アルツハイマー病のための新興の幹細胞に基づく治療法
    • アルツハイマー病のための開発中の細胞療法
    • 法規制スケジュール
  • パーキンソン病のための新興の幹細胞に基づく治療法
    • パーキンソン病のための開発中の細胞療法
    • 法規制スケジュール
  • 脊椎損傷のための新興の幹細胞に基づく治療法
    • 脊椎損傷のための開発中の細胞療法
    • 法規制スケジュール
  • 虚血性脳梗塞後の新興の幹細胞に基づく治療法
    • 虚血性脳梗塞のための開発中の細胞療法
    • 法規制スケジュール
  • 米国の神経疾患関連細胞療法製品市場

付録:企業リスト

参考文献

目次
Product Code: A427

Tissue engineering, or regenerative medicine, represents a promising therapeutic possibility for the treatment of aggressive and deadly diseases. Cellular therapies for cardiovascular disease (CVD) and neurological disease represent potential billion dollar markets that could offer a viable therapeutic option for a sizable patient population that has exhausted other therapeutic alternatives. Over 35 novel cellular therapies for cardiovascular and neurological disease are currently in development internationally, and in the United States (U.S.).

Content included in this report includes:

  • emerging cellular therapies for cardiovascular and neurological diseases;
  • companies and biotech firms developing novel cellular therapies;
  • a prospective regulatory approval forecast for cellular therapy products currently in development for cardiovascular and neurological diseases; and,
  • a speculative market analysis predicting the potential overall market values for cardiovascular and neurological disease stem cell therapies.

The scope of the analysis of this report covers companies developing novel cellular therapeutics for the treatment of debilitating and deadly diseases that currently lack adequate therapeutic intervention. Cardiovascular disease-related conditions with cellular therapies in development are discussed in Chapter 2 of this report, which covers acute myocardial infarction, critical limb ischemia, heart failure, and bioengineered vascular grafts. Neurological conditions/diseases discussed in Chapter 3 of this report include Alzheimer's disease, ischemic stroke, Parkinson's disease, and spinal cord injury.

Table of Contents

EXECUTIVE SUMMARY

  • i. Methodology

1. TISSUE ENGINEERING AND CELLULAR THERAPY TOOLS AND TECHNIQUES

  • 1.1. Biomaterials
    • 1.1.1. Biologically Derived Biomaterials
      • 1.1.1.1. Collagen
      • 1.1.1.2. Xenogenic Tissue
    • 1.1.2. Genetically Engineered Biomaterials
      • 1.1.2.1. Deoxyribonucleic Acid Transfection Vectors
      • 1.1.2.2. Genetically Manipulated Cells
      • 1.1.2.3. Three-Dimensional Polymer Technology
      • 1.1.2.4. Transgenics
      • 1.1.2.5. Fibroblasts
      • 1.1.2.6. Immortalized Neural Stem Cells
      • 1.1.2.7. Gene Activated Matrices
    • 1.1.3. Hybrid Biomaterials
    • 1.1.4. Synthetic Biomaterials
    • 1.1.5. Scaffolds
    • 1.1.6. Vascular Grafts
  • 1.2. Cell Culture Technology
    • 1.2.1. Bioreactors
      • 1.2.1.1. Flatbed Perfusion Systems
      • 1.2.1.2. Hollow Fiber Bioreactor Systems
      • 1.2.1.3. Cell Suspension Systems
      • 1.2.1.4. Disposable Bioreactors
  • 1.3. Stem Cell Technology
    • 1.3.1. Cell Extraction and Expansion
  • 1.4. Immunoisolation Technology
    • 1.4.1. Chimeric Immunity
    • 1.4.2. Cell Encapsulation Technology

2. EMERGING APPLICATIONS OF TISSUE ENGINEERING AND CELL TRANSPLANTATION IN CARDIOVASCULAR DISEASE MANAGEMENT

  • 2.1. Cellular Therapy and Tissue Engineering
    • 2.1.1. Skeletal Myoblasts
    • 2.1.2. Bone Marrow-Derived Stem Cells
    • 2.1.3. Adipose Tissue-Derived Stem Cells
    • 2.1.4. Cardiac Stem Cells
    • 2.1.5. Human Embryonic Stem Cells
    • 2.1.6. Induced Pluripotent Stem Cells
  • 2.2. Cellular Therapy Administration
  • 2.3. Clinical Experience with Stem Cell-Based Myocardial Tissue Repair and Regeneration
  • 2.4. Cellular Therapies for Myocardial Repair and Regeneration in Development
    • 2.4.1. Athersys
    • 2.4.2. Baxter
    • 2.4.3. Bioheart, Inc.
    • 2.4.4. Capricor Therapeutics
    • 2.4.5. Cytori Therapeutics
    • 2.4.6. Mesoblast Ltd.
    • 2.4.7. NeoStem
    • 2.4.8. Osiris Therapeutics
    • 2.4.9. Terumo Corporation
    • 2.4.10. Vericel
    • 2.4.11. Conceivable Regulatory Timetable
  • 2.5. Emerging Cellular Therapies for Limb Salvage in Critical Limb Ischemia Patients
    • 2.5.1. Therapeutic Angiogenesis
      • 2.5.1.1. Growth Factor/Gene-Based Angiogenic Therapy
      • 2.5.1.2. Stem Cell-Based Angiogenic Therapy
      • 2.5.1.3. Therapeutic Angiogenesis Products in Development
        • 2.5.1.3.1. Biomet Biologics
        • 2.5.1.3.2. Harvest Technologies
        • 2.5.1.3.3. Pluristem Therapeutics
        • 2.5.1.3.4. Taxus Cardium Pharmaceuticals Group
      • 2.5.1.4. Conceivable Regulatory Timetable
  • 2.6. Bioengineered Vascular Conduits
    • 2.6.1. Products in Development
    • 2.6.2. Conceivable Regulatory Timetable
  • 2.7. Current and Emerging U.S. Market for Cardiovascular Disease-Related Tissue Engineering and Cellular Therapy Products
  • Exhibit 2-1: Comparative Advantages and Disadvantages of Selected Stem Cell Grafts for Myocardial Repair and Regeneration
  • Exhibit 2-2: Selected Myocardial Cellular Repair and Regeneration Therapies in Development
  • Exhibit 2-3: Estimated Growth of Potential Myocardial Cellular Repair and Regeneration Caseloads, U.S., 2017-2020
  • Exhibit 2-4: Estimated Growth of Potential Therapeutic Angiogenesis Cellular Therapy Caseloads, U.S., 2017-2022
  • Exhibit 2-5: Estimated Growth of Potential Bioengineered Vascular Graft Caseloads, U.S., 2017-2022
  • Exhibit 2-6: Tissue Engineered Cardiac and Vascular Products, Expected Product Launch, by Indication
  • Exhibit 2-7: Tissue Engineered Cardiac and Vascular Products, Estimated Market Forecast, 2017 and 2022

3. EMERGING APPLICATIONS OF TISSUE ENGINEERING AND CELL TRANSPLANTATION IN NEUROLOGICAL DISEASE MANAGEMENT

  • 3.1. Types of Cells Used for Cellular Therapies in Development
    • 3.1.1. Bone Marrow-Derived Stem Cells
    • 3.1.2. Adipose Tissue-Derived Stem Cells
    • 3.1.3. Embryonic Stem Cells
    • 3.1.4. Induced Pluripotent Stem Cells
    • 3.1.5. Mesenchymal Stem Cells
    • 3.1.6. Neural Stem Cells
  • 3.2. Emerging Stem Cell-Based Therapies for Alzheimer's Disease
    • 3.2.1. Cellular Therapies in Development for Alzheimer's Disease
      • 3.2.1.1. Chinese Academy of Military Medical Sciences
      • 3.2.1.2. Medipost
      • 3.2.1.3. Neuralstem
      • 3.2.1.4. StemCells, Inc.
    • 3.2.2. Conceivable Regulatory Timetable
  • 3.3. Emerging Stem Cell-Based Therapies for Parkinson's Disease
    • 3.3.1. Cellular Therapies for Parkinson's Disease in Development
      • 3.3.1.1. Bundang CHA Hospital
      • 3.3.1.2. Fondazione IRCCS Ca'Granda, Ospedale Maggiore Policlinico
      • 3.3.1.3. Instituto de Medicina Regenerativa/Ageless Regenerative Institute
      • 3.3.1.4. International Stem Cell Corporation
      • 3.3.1.5. Neuralstem
    • 3.3.2. Conceivable Regulatory Timetable
  • 3.4. Emerging Stem Cell-Based Therapies for Spinal Cord Injury
    • 3.4.1. Spinal Cord Injury Cellular Therapies in Development
      • 3.4.1.1. Bukwang Pharmaceutical
      • 3.4.1.2. The General Hospital of Chinese Armed Police Forces
      • 3.4.1.3. Hospital Sao Rafael
      • 3.4.1.4. Neuralstem
      • 3.4.1.5. Neurogen Brain and Spine Insitute
      • 3.4.1.6. Pharmicell
      • 3.4.1.7. StemCells, Inc.
      • 3.4.1.8. Translational Biosciences
    • 3.4.2. Conceivable Regulatory Timetable
  • 3.5. Emerging Stem Cell-Based Therapies for Post-Ischemic Stroke
    • 3.5.1. Stem Cell Therapies for Ischemic Stroke in Development
      • 3.5.1.1. Athersys
      • 3.5.1.2. Ecron Acunova
      • 3.5.1.3. International Stem Cell Corporation
      • 3.5.1.4. Pharmicell
      • 3.5.1.5. ReNeuron, Ltd.
      • 3.5.1.6. SanBio
      • 3.5.1.7. Stemedica
      • 3.5.1.8. Stempeutics
      • 3.5.1.9. University of Irvine
    • 3.5.2. Conceivable Regulatory Timetable
  • 3.6. Potential U.S. Market for Neurological Disease-Related Cellular Therapy Products
  • Exhibit 3-1: Estimated Growth of Potential Early-Stage Alzheimer's Cellular Therapy Caseloads, U.S., 2015-2020
  • Exhibit 3-2: Estimated Growth of Early-Stage Parkinson's Disease Cellular Therapy Caseloads, U.S., 2015-2020
  • Exhibit 3-3: Estimated Growth of Potential Spinal Cord Injury Cellular Therapy Caseloads, U.S., 2015-2020
  • Exhibit 3-4: Estimated Growth of Potential Ischemic Stroke Cellular Therapy Caseloads, U.S., 2015-2020
  • Exhibit 3-5: Tissue Engineered Neurological Disease Products, Expected Product Launch, by Indication
  • Exhibit 3-6: Tissue Engineered Neurological Disease Products, Estimated Market Forecast, 2020

APPENDIX: COMPANY LISTING

BIBLIOGRAPHY

Back to Top